Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Int J Mol Sci ; 17(5)2016 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-27213362

RESUMO

With the safety of existing nuclear power plants being brought into question after the Fukushima disaster and the increased level of concern over terrorism-sponsored use of improvised nuclear devices, it is more crucial to develop well-defined radiation injury markers in easily accessible biofluids to help emergency-responders with injury assessment during patient triage. Here, we focused on utilizing ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) to identify and quantitate the unique changes in the urinary excretion of two metabolite markers, calcitroic acid and citrulline, in mice induced by different forms of irradiation; external γ irradiation at a low dose rate (LDR) of 3.0 mGy/min and a high dose rate (HDR) of 1.1 Gy/min, and internal exposure to Cesium-137 ((137)Cs) and Strontium-90 ((90)Sr). The multiple reaction monitoring analysis showed that, while exposure to (137)Cs and (90)Sr induced a statistically significant and persistent decrease, similar doses of external γ beam at the HDR had the opposite effect, and the LDR had no effect on the urinary levels of these two metabolites. This suggests that the source of exposure and the dose rate strongly modulate the in vivo metabolomic injury responses, which may have utility in clinical biodosimetry assays for the assessment of exposure in an affected population. This study complements our previous investigations into the metabolomic profile of urine from mice internally exposed to (90)Sr and (137)Cs and to external γ beam radiation.


Assuntos
Calcitriol/análogos & derivados , Citrulina/urina , Raios gama/efeitos adversos , Metabolômica , Lesões Experimentais por Radiação/urina , Animais , Calcitriol/urina , Feminino , Masculino , Camundongos
2.
Am J Nephrol ; 35(5): 434-41, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22538635

RESUMO

INTRODUCTION: Calcium and phosphorus are essential to many vital physiological processes. Little is known about the net and fractional intestinal absorption of calcium and phosphorus in patients with chronic kidney disease (CKD) and their clinical and hormonal determinants. METHODS: Blood and 24-hour urine samples were collected in 20 healthy volunteers (HV) and 72 stable CKD stage 1-4 patients and analyzed for parameters of mineral metabolism including calcidiol, calcitriol, and parathyroid hormone (PTH). Dietary intake was assessed by dietary history. RESULTS: The 24-hour urinary calcium excretion, as opposed to the phosphorus excretion, showed a stepwise decrease across CKD stages (median of 219, 84, 40, and 22 mg/day in HV and patients with CKD stages 1-2, 3 and 4, respectively). Younger age, high serum calcitriol, and high estimated GFR were associated with a high 24-hour urinary calcium excretion. High serum calcitriol levels and dietary phosphorus intake were associated with a high 24-hour urinary phosphorus excretion. The fractional intestinal calcium absorption, as estimated by the urinary-to-ingested calcium ratio, decreased across CKD stages. CONCLUSIONS: The 24-hour urinary excretion of calcium, as opposed to phosphorus, is markedly decreased in CKD, even in early-stage disease. This is partly explained by low calcitriol levels and older age. Assuming a neutral calcium balance at the time of urine collection, we infer that net intestinal calcium absorption may be severely impaired in CKD.


Assuntos
Calcifediol/sangue , Calcitriol/sangue , Cálcio da Dieta/metabolismo , Absorção Intestinal/fisiologia , Hormônio Paratireóideo/sangue , Fósforo/sangue , Insuficiência Renal Crônica/sangue , Adulto , Idoso , Bélgica , Calcifediol/urina , Calcitriol/urina , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fósforo/urina , Insuficiência Renal Crônica/urina
3.
Calcif Tissue Int ; 59(3): 174-8, 1996 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8694894

RESUMO

The oophorectomized (OOX) rat has been proposed as a good model of postmenopausal osteoporosis in women. The aim of this study was to compare the effect of OOX in 6-month-old rats to the effects of menopause in women with respect to bone mass, the renal handling of calcium and phosphorus, and calcitropic hormones. To more closely replicate the human situation the rats were pair fed a 0.1% calcium diet. Thirty four, 6-month-old rats were randomized to sham operation or OOX. Whole body and regional bone density was performed at baseline and 6 weeks postoperation. Blood and 24-hour urine samples were obtained at baseline, 1, 3, and 6 weeks and assayed for various biochemical variables, parathyroid hormone (PTH), and calcitriol. The OOX rats lost significantly more bone than the sham-operated rats (change in global bone mineral density, sham -1.7 +/- 2.0%, OOX -3.9 +/- 2.6%, P < 0.001). In the OOX animals, an increase in the 24-hour urine calcium was observed at 1 and 3 weeks, which had returned to sham-operated levels by 6 weeks. In the whole group, the increase in urine calcium at 1 week was negatively correlated with the change in bone mass at 6 weeks (r = -0.39, P = 0. 029). OOX resulted in an increased filtered load of calcium and phosphorus. There was an increase in the maximal renal tubular reabsorption of phosphorus (TmP-GFR) but no clear change in renal calcium handling. Neither calcitriol nor parathyroid hormone showed a significant change as a result of OOX. As in postmenopausal women, following oophorectomy in the rat, there was significant generalized bone loss and a negative calcium balance. This was associated with an initial rise in urine calcium due to a rise in the filtered calcium load; plasma phosphorus and TmP-GFR also rose. The rat model may differ from postmenopausal bone loss in that the initial rise in urine calcium was not present at later time points as occurs in natural menopause in women. Calcitropic hormone levels did not change. This study has shown that the 6-month-old OOX rat fed a 0.1% calcium diet has many similarities of calcium and phosphorus homeostasis to that seen at menopause in women.


Assuntos
Densidade Óssea/fisiologia , Cálcio/metabolismo , Estrogênios/deficiência , Rim/metabolismo , Osteoporose Pós-Menopausa/fisiopatologia , Fósforo/metabolismo , Absorciometria de Fóton , Análise de Variância , Animais , Biomarcadores/sangue , Biomarcadores/urina , Calcitriol/sangue , Calcitriol/urina , Cálcio/urina , Cálcio da Dieta/administração & dosagem , Cálcio da Dieta/farmacocinética , Modelos Animais de Doenças , Feminino , Taxa de Filtração Glomerular , Humanos , Menopausa , Ovariectomia , Hormônio Paratireóideo/sangue , Hormônio Paratireóideo/urina , Fósforo na Dieta/administração & dosagem , Fósforo na Dieta/farmacocinética , Ratos , Ratos Sprague-Dawley
4.
Lancet ; 335(8700): 1240-3, 1990 May 26.
Artigo em Inglês | MEDLINE | ID: mdl-1971321

RESUMO

Urinary excretion of oxalate and phosphate was measured in twelve vitamin-D-treated, phosphate-supplemented patients with X-linked hypophosphataemia (XLH; four children, eight adolescents and adults) to investigate possible causative factors of nephrocalcinosis other than calcium. Oxalate excretion correlated highly with urinary phosphate excretion and with intake of phosphate supplements corrected for body surface area. Young children received the highest relative doses of phosphate (range 2.27-10.8 g/1.73 m2 daily) and their urinary oxalate excretion was very high (0.94-3.38 mmol/1.73 m2 daily). The urinary oxalate excretion of untreated adults with XLH was within normal limits. Six patients had evidence of nephrocalcinosis on ultrasound. The high urinary oxalate excretion in phosphate-supplemented XLH may be seen as a special type of enteric hyperoxaluria, in which the conditions of calcium-oxalate crystal precipitation could be reached even at normal levels of urinary calcium excretion. Urinary excretion of both calcium and oxalate should therefore be monitored during treatment in young XLH patients.


Assuntos
Hiperoxalúria/complicações , Hipofosfatemia Familiar/urina , Nefrocalcinose/etiologia , Fosfatos/urina , Raquitismo/tratamento farmacológico , Vitamina D/uso terapêutico , Adolescente , Adulto , Calcitriol/uso terapêutico , Calcitriol/urina , Cálcio/urina , Oxalato de Cálcio/urina , Criança , Pré-Escolar , Creatinina/urina , Estudos de Avaliação como Assunto , Feminino , Ligação Genética , Glicolatos/urina , Humanos , Hiperoxalúria/urina , Hipofosfatemia Familiar/complicações , Hipofosfatemia Familiar/tratamento farmacológico , Lactente , Masculino , Nefrocalcinose/diagnóstico , Nefrocalcinose/urina , Fosfatos/administração & dosagem , Fosfatos/uso terapêutico , Raquitismo/urina , Ultrassonografia , Cromossomo X
5.
J Bone Miner Res ; 3(6): 699-706, 1988 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-2855193

RESUMO

Female nude mice were infused with 5.0, 3.0, or 1.0 micrograms/day of synthetic human parathyroid hormone-related protein (PTHrP) or control diluent with subcutaneous Alzet miniosmotic pumps for 7 days. Serum calcium was increased (p less than 0.01) on days 3 (13.9 mg/dl), 5 (13.6 mg/dl), and 7 (12.9 mg/dl) in mice infused with PTHrP at 5.0 micrograms/day compared with control nude mice (8.8 mg/dl). Serum calcium was significantly increased to a lesser degree in mice infused with 1.0 micrograms/day PTHrP (day 3) or 3.0 micrograms/day (days 3 and 7). Serum phosphorus was decreased (p less than 0.01) in all three groups of mice infused with PTHrP (4.6 mg/dl, 5.0 micrograms/day; 6.7 mg/dl, 3.0 micrograms/day; and 6.4 mg/dl, 1.0 micrograms/day) compared with controls (8.5 mg/dl). Serum 1,25-dihydroxycholecalciferol was increased (2.4-fold) in mice infused with PTHrP (5.0 and 3.0 micrograms/day). The urinary calcium-creatinine ratio (0.74 compared with 0.034 in controls) was increased (p less than 0.03) in mice infused with PTHrP (5.0 micrograms/day), but the urinary phosphorus-creatinine ratio was not different from that in controls. The urinary cAMP-creatinine ratio was increased (1.6-fold) in mice infused with PTHrP (5.0 micrograms/day). Static bone histomorphometry revealed increased (p less than 0.01) trabecular bone area, osteoblast perimeter, osteoid perimeter, osteoid width, wall width, osteoclast area, number of osteoclasts, and osteoclast perimeter in trabecular bone of lumbar vertebrae from mice infused with PTHrP. Dynamic bone histomorphometry demonstrated increased (p less than 0.01) double-labeled perimeter, mineralizing perimeter, and bone formation rate. The results of this study indicated that PTHrP increased serum calcium and 1,25-dihydroxycholecalciferol, decreased serum phosphorus, increased urinary excretion of calcium, phosphorus, and cAMP, and increased both bone resorption and formation in nude mice. PTHrP mimics the action of native PTH in vivo and is likely to be an important protein in the pathogenesis of humoral hypercalcemia of malignancy.


Assuntos
Desenvolvimento Ósseo/efeitos dos fármacos , Reabsorção Óssea/efeitos dos fármacos , Proteínas de Neoplasias/farmacologia , Hormônio Paratireóideo/farmacologia , Animais , Calcitriol/urina , Cálcio/metabolismo , Creatinina/urina , AMP Cíclico/urina , Feminino , Humanos , Bombas de Infusão , Vértebras Lombares , Camundongos , Camundongos Nus , Minerais/metabolismo , Proteína Relacionada ao Hormônio Paratireóideo , Fósforo/metabolismo
6.
Am J Med ; 72(1): 25-32, 1982 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-6277190

RESUMO

We have used a low-calcium diet providing only 2 mg/kg (body weight) per 24 hours of calcium to distinguish between "renal" and "absorptive" idiopathic hypercalciuria. Sixteen of 27 hypercalciuric subjects excreted calcium in excess of intake during days seven, eight and nine of he diet, suggesting some element of renal hypercalciuria; however, all patients had low or normal serum PTH and urine cAMP levels. In general, fasting urine calcium was elevated in these 16 subjects and normal in the remaining 11, who conserved calcium more normally. SErum 1,25(OH)2D3 levels were the same in patients and normal subjects, even though PTH levels of the patients were below those of he normal subjects. Urine magnesium excretion and phosphorus excretion were both increased in the patients who excreted calcium in excess of intake. Our findings suggest that renal and absorptive hypercalciuria may not be distinct entities but rather the two extremes of a continuum of behavior. A uniform elevation of intestinal calcium absorption and a variable defect of renal calcium reabsorption could explain our results far better than the hypothesis of distinct absorptive and renal forms of hypercalciuria.


Assuntos
Calcitriol/sangue , Cálcio da Dieta/uso terapêutico , Cálcio/urina , Hormônio Paratireóideo/sangue , Calcitriol/urina , Cálcio/sangue , Creatinina/urina , AMP Cíclico/urina , Humanos , Magnésio/sangue , Magnésio/urina , Fosfatos/sangue , Fósforo/urina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA